Analysis of the latest market price of dacomitinib in 2025

Dacomitinib (Dacomitinib), as a second-generation targeted drug targeting EGFR mutation-positive non-small cell lung cancer, has attracted much attention in recent years for its performance in the domestic market. In 2025, the original drug dacomitinib has been successfully launched in China and has been included in the national medical insurance reimbursement catalog, which has reduced the financial burden of medication for patients. It is reported that the price of dacomitinib original drug in the domestic market of 15mg*30 tablets is about 5,680 yuan. After reimbursement by medical insurance, the actual amount paid by patients is usually reduced to about 1,300 yuan, which greatly improves patients' medication accessibility and treatment compliance.

In the international market, the price of dacomitinib is relatively high. Taking the European market as an example, the original version of dacomitinib with specifications of 45mg*30 tablets is priced at about 24,000 yuan, which is significantly higher than domestic prices. This is mainly affected by multiple factors such as pricing strategies of pharmaceutical companies, import taxes and fees, exchange rate fluctuations, and local medical insurance policies. Although the high price in Europe increases the cost of medication, it also reflects the drug's technological leadership and therapeutic value in the local market.

In order to meet the medication needs of more patients, generic dacomitinib produced by Lucius Pharmaceuticals of Laos has also appeared on the market. The specifications of this version are mostly similar to the original drugs, and the price is about 1,000 yuan, which is far lower than the price of domestic and European original drugs. The emergence of generic drugs provides patients with an affordable choice, but when using them, attention must be paid to drug quality and legal channels to ensure efficacy and safety.

Overall, 2025 The market price of dacomitinib shows a reasonable range supported by domestic medical insurance. At the same time, high overseas prices and low prices of generic drugs coexist. When choosing, patients should reasonably choose the appropriate version of dacomitinib based on their own financial situation, treatment needs and doctor's advice to ensure treatment effects and medication safety. As the market continues to mature and policies are optimized, the price and supply of dacomitinib are expected to further improve.

Reference: https://go.drugbank.com/drugs/